A molecular biologist by training, Gini has more than 16 years of experience turning cutting-edge scientific concepts into products that benefit patients. As CEO of NuMedii, Gini structured the company’s critical partnerships with some of the world’s largest pharmaceutical companies including Allergan, Astellas and Aptalis, and raised the initial rounds of financing. Before NuMedii, she helped companies identify optimal markets and whole-product solutions for their groundbreaking technologies, including Affymetrix and iPierian, and led innovation at Children’s Hospital Boston, where she focused on the creation of new devices for the tiniest of patients. Gini has helped commercialize early-stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million. She received her MS from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.

Heather is leading research discovery and development at NuMedii, successfully translating AI hits into novel therapeutics. She has more than 15 years of experience in large and small molecule drug discovery and development, and more than 30 publications in top-tier journals with research focused on diverse pathways in immunology, neuroscience, and fibrotic diseases. In her most recent role at Amgen, Heather spearheaded multiple immune modulatory therapies, as well as building and managing a robust team of scientists and associates focused on filling the pipeline with new therapies for fibrotic and inflammatory diseases, and immuno-oncology. She holds a PhD in Neuroscience from the University of North Carolina at Chapel Hill and completed a National Multiple Sclerosis Society postdoctoral fellowship at Harvard Medical School and the Dana-Farber Cancer Institute.

Linda bridges the connection between technology and drug development at NuMedii. She brings 20 years’ experience leading drug development programs for industry leading and start-up biotechnology and life science companies across a variety of platforms – small molecule, protein, polymer, cellular and antisense therapeutics – as well as a range of drug delivery devices. In addition to 10 years as a principal at Virtualizing Drug Development and IND Enabling Consulting, Linda held senior leadership positions at several companies focused on cardiovascular disease and oncology including AeroGen and Genentech. Linda has a BS in Biochemistry from the UC Davis, a PhD in Pharmaceutical Chemistry from UC San Francisco, and was a Postdoctoral Fellow, Department of Chemistry and Biochemistry, UC Santa Cruz.